Men have higher JAK2 V617F VAF in CD34⁺ cells across different phenotypes but not in neutrophils, and their survival outcomes are less dependent on JAK2 V617F VAF change per year. (A) The neutrophil JAK2 V617F VAF in men was not higher compared with women across the whole cohort (P = .528), and among patients with ET (P = .290), whereas among patients with PV, men exhibited a trend of increased JAK2 V617F VAF, but the difference did not reach significance (P = .07). Among patients with PMF, women had higher JAK2 V617F VAF compared with men (P = .037), whereas differences did not reach significance among patients with sMF (P = .160). (B) The CD34⁺ cell JAK2 V617F VAF in men was higher compared with women across the whole cohort (P < .001), among patients with ET (P = .004), and among patients with PV (P = .005); there was no difference among PMF (P = .618) and sMF (P = .720) patients. (C) Kaplan-Meier analysis showed that women with JAK2 V617F VAF change per year >0.5% have worse survival compared with women with ≤0.5% change per year (P = .013). (D) Kaplan-Meier analysis of men showed no difference in the survival of those with JAK2 V617F VAF change >0.5% per year (P = .4). All MPN = cohort including all the MPN phenotypes.